These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 10637240

  • 1. Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer.
    Conley B, O'Shaughnessy J, Prindiville S, Lawrence J, Chow C, Jones E, Merino MJ, Kaiser-Kupfer MI, Caruso RC, Podgor M, Goldspiel B, Venzon D, Danforth D, Wu S, Noone M, Goldstein J, Cowan KH, Zujewski J.
    J Clin Oncol; 2000 Jan; 18(2):275-83. PubMed ID: 10637240
    [Abstract] [Full Text] [Related]

  • 2. Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide.
    Sabichi AL, Modiano MR, Lee JJ, Peng YM, Xu MJ, Villar H, Dalton WS, Lippman SM.
    Clin Cancer Res; 2003 Jul; 9(7):2400-5. PubMed ID: 12855611
    [Abstract] [Full Text] [Related]

  • 3. Breast cancer chemoprevention: studies with 4-HPR alone and in combination with tamoxifen using circulating growth factors as potential surrogate endpoints.
    Decensi A, Formelli F, Torrisi R, Costa A.
    J Cell Biochem Suppl; 1993 Jul; 17G():226-33. PubMed ID: 8007703
    [Abstract] [Full Text] [Related]

  • 4. Experimental studies on the effects of the combined use of N-(4-hydroxyphenyl)retinamide (4-HPR) and tamoxifen (TAM) for estrogen receptor (ER)-negative breast cancer.
    Aoyama Y.
    Kurume Med J; 2002 Jul; 49(1-2):27-33. PubMed ID: 12235869
    [Abstract] [Full Text] [Related]

  • 5. Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women.
    Decensi A, Robertson C, Guerrieri-Gonzaga A, Serrano D, Cazzaniga M, Mora S, Gulisano M, Johansson H, Galimberti V, Cassano E, Moroni SM, Formelli F, Lien EA, Pelosi G, Johnson KA, Bonanni B.
    J Clin Oncol; 2009 Aug 10; 27(23):3749-56. PubMed ID: 19597031
    [Abstract] [Full Text] [Related]

  • 6. Fenretinide breast cancer prevention trial: drug and retinol plasma levels in relation to age and disease outcome.
    Formelli F, Camerini T, Cavadini E, Appierto V, Villani MG, Costa A, De Palo G, Di Mauro MG, Veronesi U.
    Cancer Epidemiol Biomarkers Prev; 2003 Jan 10; 12(1):34-41. PubMed ID: 12540501
    [Abstract] [Full Text] [Related]

  • 7. Relationship among pharmacokinetics and pharmacodynamics of fenretinide and plasma retinol reduction in neuroblastoma patients.
    Formelli F, Cavadini E, Luksch R, Garaventa A, Appierto V, Persiani S.
    Cancer Chemother Pharmacol; 2010 Oct 10; 66(5):993-8. PubMed ID: 20532509
    [Abstract] [Full Text] [Related]

  • 8. The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients.
    Torrisi R, Pensa F, Orengo MA, Catsafados E, Ponzani P, Boccardo F, Costa A, Decensi A.
    Cancer Res; 1993 Oct 15; 53(20):4769-71. PubMed ID: 8402658
    [Abstract] [Full Text] [Related]

  • 9. Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients.
    Formelli F, Carsana R, Costa A, Buranelli F, Campa T, Dossena G, Magni A, Pizzichetta M.
    Cancer Res; 1989 Nov 01; 49(21):6149-52. PubMed ID: 2529028
    [Abstract] [Full Text] [Related]

  • 10. Chemoprevention of breast cancer with fenretinide (4-HPR): study of long-term visual and ophthalmologic tolerability.
    Mariani L, Formelli F, De Palo G, Manzari A, Camerini T, Campa T, Di Mauro MG, Crippa A, Delle Grottaglie M, Del Vecchio M, Marubini E, Costa A, Veronesi U.
    Tumori; 1996 Nov 01; 82(5):444-9. PubMed ID: 9063520
    [Abstract] [Full Text] [Related]

  • 11. Identification of the fenretinide metabolite 4-oxo-fenretinide present in human plasma and formed in human ovarian carcinoma cells through induction of cytochrome P450 26A1.
    Villani MG, Appierto V, Cavadini E, Valsecchi M, Sonnino S, Curley RW, Formelli F.
    Clin Cancer Res; 2004 Sep 15; 10(18 Pt 1):6265-75. PubMed ID: 15448016
    [Abstract] [Full Text] [Related]

  • 12. Tamoxifen and fenretinide in women with metastatic breast cancer.
    Zujewski J, Pai L, Wakefield L, Giusti R, Dorr FA, Flanders C, Caruso R, Kaiser M, Goodman L, Merino M, Gossard M, Noone MA, Denicoff A, Venzon D, Cowan KH, O'Shaughnessy JA.
    Breast Cancer Res Treat; 1999 Oct 15; 57(3):277-83. PubMed ID: 10617304
    [Abstract] [Full Text] [Related]

  • 13. Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complex.
    Maurer BJ, Kalous O, Yesair DW, Wu X, Janeba J, Maldonado V, Khankaldyyan V, Frgala T, Sun BC, McKee RT, Burgess SW, Shaw WA, Reynolds CP.
    Clin Cancer Res; 2007 May 15; 13(10):3079-86. PubMed ID: 17505011
    [Abstract] [Full Text] [Related]

  • 14. Retinoid metabolism in the prostate: effects of administration of the synthetic retinoid N-(4-hydroxyphenyl)retinamide.
    Lewis KC, Hochadel JF.
    Cancer Res; 1999 Dec 01; 59(23):5947-55. PubMed ID: 10606240
    [Abstract] [Full Text] [Related]

  • 15. Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer.
    Camerini T, Mariani L, De Palo G, Marubini E, Di Mauro MG, Decensi A, Costa A, Veronesi U.
    J Clin Oncol; 2001 Mar 15; 19(6):1664-70. PubMed ID: 11250995
    [Abstract] [Full Text] [Related]

  • 16. N-(4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium.
    Kurie JM, Lee JS, Khuri FR, Mao L, Morice RC, Lee JJ, Walsh GL, Broxson A, Lippman SM, Ro JY, Kemp BL, Liu D, Fritsche HA, Xu X, Lotan R, Hong WK.
    Clin Cancer Res; 2000 Aug 15; 6(8):2973-9. PubMed ID: 10955773
    [Abstract] [Full Text] [Related]

  • 17. A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer.
    Colombo N, Formelli F, Cantù MG, Parma G, Gasco M, Argusti A, Santinelli A, Montironi R, Cavadini E, Baglietto L, Guerrieri-Gonzaga A, Viale G, Decensi A.
    Cancer Epidemiol Biomarkers Prev; 2006 Oct 15; 15(10):1914-9. PubMed ID: 17035399
    [Abstract] [Full Text] [Related]

  • 18. Chemoprevention of MNU-induced mammary tumors in the mature rat by 4-HPR and tamoxifen.
    Moon RC, Kelloff GJ, Detrisac CJ, Steele VE, Thomas CF, Sigman CC.
    Anticancer Res; 1992 Oct 15; 12(4):1147-53. PubMed ID: 1386970
    [Abstract] [Full Text] [Related]

  • 19. Chemoprevention of skin carcinogenesis by phenylretinamides: retinoid receptor-independent tumor suppression.
    Xu H, Cheepala S, McCauley E, Coombes K, Xiao L, Fischer SM, Clifford JL.
    Clin Cancer Res; 2006 Feb 01; 12(3 Pt 1):969-79. PubMed ID: 16467112
    [Abstract] [Full Text] [Related]

  • 20. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism.
    Maurer BJ, Melton L, Billups C, Cabot MC, Reynolds CP.
    J Natl Cancer Inst; 2000 Dec 06; 92(23):1897-909. PubMed ID: 11106681
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.